Skip to main content
SpringerLink
Log in

Clinical Staging of Ovarian Cancer

  • Protocol
  • First Online:
Ovarian Cancer

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2424))

Abstract

Ovarian cancer may arise from any of the histologic portions of the ovary including the epithelium, stroma, or germ cells. Of these, high-grade serous carcinoma arising from the epithelium of the ovary is the most common type. The clinical management and prognosis of ovarian cancer depend upon the stage of the cancer. Cancer stage is the extent to which the cancer has spread from its site of origin. For ovarian cancer, staging guidelines are determined by FIGO, the Fédération Internationale de Gynécologie et d’Obstétrique. The stage of ovarian cancer is determined by performing surgery to remove the ovaries and other gynecologic organs as well as lymph nodes and other tissues where the cancer may have spread. The histologic specimens from this surgery provide information from which the stage can be determined. In more advanced cases, this surgery may also include procedures to remove other areas of cancer. The stage of ovarian cancer guides treatment and is also the most important factor in ovarian cancer prognosis. Most epithelial ovarian cancers are diagnosed in advanced stages and are treated with surgery and chemotherapy. Despite aggressive treatment, the survival of patients with advanced stage epithelial ovarian cancer remains low, and more effective diagnostic and therapeutic approaches are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. FIGO Ovarian Cancer Staging Guidelines (January 2014). (2014) Society of Gynecologic Oncology. https://www.sgo.org/resources/new-figo-ovarian-cancer-staging-guidelines/. Accessed October 2020

  2. Chi DS, Berchuck A, Dizon DS, Yashar CM (2017) Principles and practice of gynecologic oncology, 7th edn. Wolters Kluwer Health, Philadelphia, Pennsylvania

    Google Scholar 

  3. Prat J (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1–5. https://doi.org/10.1016/j.ijgo.2013.10.001

    Article  PubMed  Google Scholar 

  4. Prat J (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 124(1):1–5. https://doi.org/10.1016/j.ijgo.2013.10.001

    Article  Google Scholar 

  5. Cancer Staging System. (2020) American Joint Committee on Cancer. https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx

  6. What is Cancer Staging? (2020) American Joint Committee on Cancer. https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx

  7. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT (2010) Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol 116(2 Pt 1):269–273. https://doi.org/10.1097/AOG.0b013e3181e7961d

    Article  PubMed  PubMed Central  Google Scholar 

  8. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D (2003) Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197(2):198–205. https://doi.org/10.1016/s1072-7515(03)00234-5

    Article  PubMed  Google Scholar 

  9. Berek JS, Hacker NF (2014) Berek & Hacker’s gynecologic oncology, 6th edn. Wolters Kluwer Health, Philadelphia, Pennsylvania

    Google Scholar 

  10. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322(15):1021–1027. https://doi.org/10.1056/nejm199004123221501

    Article  CAS  PubMed  Google Scholar 

  11. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-adjuvant ChemoTherapy in ovarian neoplasm trial. J Natl Cancer Inst 95(2):113–125

    Article  CAS  PubMed  Google Scholar 

  12. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM (2003) International collaborative ovarian neoplasm trial 1 and adjuvant ChemoTherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95(2):105–112

    Article  PubMed  Google Scholar 

  13. Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177(3):1053–1064. https://doi.org/10.2353/ajpath.2010.100105

    Article  PubMed  PubMed Central  Google Scholar 

  14. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim J-W, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380(9):822–832. https://doi.org/10.1056/NEJMoa1808424

    Article  PubMed  Google Scholar 

  15. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol 27(9):1419–1425. https://doi.org/10.1200/jco.2008.19.1684

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473–2483. https://doi.org/10.1056/NEJMoa1104390

    Article  CAS  PubMed  Google Scholar 

  17. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257. https://doi.org/10.1016/S0140-6736(14)62223-6

    Article  PubMed  Google Scholar 

  18. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953. https://doi.org/10.1056/NEJMoa0908806

    Article  CAS  PubMed  Google Scholar 

  19. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical oncology clinical practice guideline. Gynecol Oncol 143(1):3–15. https://doi.org/10.1016/j.ygyno.2016.05.022

    Article  PubMed  PubMed Central  Google Scholar 

  20. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120(3):612–618. https://doi.org/10.1097/AOG.0b013e318264f794

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota Medical School, Minneapolis, MN, USA

    Andrea S. O’Shea

Authors
  1. Andrea S. O’Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea S. O’Shea .

Editor information

Editors and Affiliations

  1. Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA

    Pamela K. Kreeger

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

O’Shea, A.S. (2022). Clinical Staging of Ovarian Cancer. In: Kreeger, P.K. (eds) Ovarian Cancer. Methods in Molecular Biology, vol 2424. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1956-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-1956-8_1

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-1955-1

  • Online ISBN: 978-1-0716-1956-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation